HEB News and Press, Hemispherx BioPharma Inc.

OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases, such as myalgic encephalomyelitis/chronic...

Hemispherx Biopharma (NYSEMKT: HEB ): Q2 GAAP EPS of -$1.07 beats by $0.65 . Cash, cash equivalents and marketable securities of $2.86B Shares  +3.8% Press Release More news on: Hemispherx Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, ,

OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report 10Q for the ...

Corindus Vascular Robotics (NYSEMKT: CVRS ) +76%  on Q2 results and being acquired by Seimens. More news on: Corindus Vascular Robotics, Inc., Vitamin Shoppe, Inc., Stamps.com Inc., Stocks on the move, Read more ...

Thinly traded nano cap Hemispherx Biopharma (NYSEMKT: HEB ) is up  24%  premarket on average volume in reaction to positive results from a Phase 1 study evaluating a combination therapy that included Ampligen (rintatolimod) in patients with recurrent ovarian cancer. More news o...

OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent ovar...

OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB ) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI algorithms following the filing of an 8-K on July 22, 2019. The two stock news organizatio...

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) is a specialty pharmaceutical company headquartered in Ocala, Florida and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders, ac...

Hemispherx Biopharma, Inc. (NYSE MKT: HEB) is a specialty pharmaceutical company headquartered in Ocala, Florida and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders, ac...

OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. Pascale joined Hemispherx in 1995 as an accounting ...